GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » Debt-to-EBITDA

Nicox (NICXF) Debt-to-EBITDA : -1.89 (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Nicox Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nicox's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $3.00 Mil. Nicox's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $19.91 Mil. Nicox's annualized EBITDA for the quarter that ended in Jun. 2023 was $-12.13 Mil. Nicox's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -1.89.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Nicox's Debt-to-EBITDA or its related term are showing as below:

NICXF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.35   Med: -0.3   Max: 0
Current: -1.34

NICXF's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs NICXF: -1.34

Nicox Debt-to-EBITDA Historical Data

The historical data trend for Nicox's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Debt-to-EBITDA Chart

Nicox Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.56 -1.35 -1.35 -1.23

Nicox Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.84 -2.32 -1.51 -1.04 -1.89

Competitive Comparison of Nicox's Debt-to-EBITDA

For the Biotechnology subindustry, Nicox's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nicox's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nicox's Debt-to-EBITDA falls into.



Nicox Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nicox's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.877 + 21.637) / -18.343
=-1.23

Nicox's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.004 + 19.914) / -12.134
=-1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.


Nicox  (OTCPK:NICXF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Nicox Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Nicox's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Nicox (NICXF) Business Description

Traded in Other Exchanges
Address
2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (NICXF) Headlines